Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes
- PMID: 11807989
- DOI: 10.1002/gcc.10026
Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes
Abstract
In this investigation, we selected PAX3/FKHR and PAX7/FKHR fusion transcript-positive and -negative alveolar rhabdomyosarcomas (ARMSs) and embryonal rhabdomyosarcomas (ERMSs) with and without anaplastic features, to ascertain genomic imbalance differences and/or similarities within these histopathologic and genetic rhabdomyosarcoma (RMS) variants. Comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) studies were performed on 45 rhabdomyosarcoma specimens consisting of 23 ARMSs and 22 ERMSs (12 ERMS cases were included from an earlier study). The anaplastic variant of RMS has not previously been subjected to CGH analysis. Overall, the most prominent imbalances were gain of chromosomes or chromosomal regions 2/2q (40%), 7/7q (31%), 8/8p (53%), 11/11q (31%), 12q13-15 (49%), 13q14 (22%), and 20/20p (31%), and loss of 1p36 (27%), 3p14-21 (22%), 9q21-22 (33%), 10q22-qter (18%), 16q (27%), 17p (22%), and 22 (22%). These gains and losses were distributed equally between ARMS and ERMS histologic subtypes (excluding 7/7q and 11/11q gain that were observed chiefly in ERMS), demonstrating that these entities are similar with respect to recurrent genomic imbalances. Moreover, genomic imbalances were also evenly distributed among the ARMS fusion transcript subtypes, providing evidence for a genetic kinship despite the absence of a fusion transcript in some cases. Genomic amplification was detected in 26% and 23% of the ARMS and ERMS cases, respectively (with nearly all of the latter subset exhibiting anaplastic features). One amplicon, involving 15q25-26, corresponds to the locus of the insulin-like growth factor type I receptor (IGF1R) gene. Amplification of IGF1R was confirmed molecularly in the cases exhibiting a 15q25-26 amplicon. In summary, these results indicate that genomic gains and losses involve alike chromosomes with similar frequencies within the histopathologic and genetic subtypes of rhabdomyosarcoma, that genomic amplification is frequent not only in the alveolar histologic subtype of rhabdomyosarcoma but also in ERMS with anaplasia, and that amplification of IGF1R possibly plays a role in the development or progression of a subset of rhabdomyosarcomas.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
-
ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.Pediatr Dev Pathol. 2009 Jul-Aug;12(4):275-83. doi: 10.2350/08-03-0434.1. Pediatr Dev Pathol. 2009. PMID: 18788887
-
Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study.Genes Chromosomes Cancer. 2000 Apr;27(4):337-44. doi: 10.1002/(sici)1098-2264(200004)27:4<337::aid-gcc1>3.0.co;2-1. Genes Chromosomes Cancer. 2000. PMID: 10719362
-
[Evidence of genetic alterations in chromosome 11 in embryonal and alveolar rhabdomyosarcoma].Verh Dtsch Ges Pathol. 1998;82:210-4. Verh Dtsch Ges Pathol. 1998. PMID: 10095436 German.
-
Classification of rhabdomyosarcoma and its molecular basis.Adv Anat Pathol. 2013 Nov;20(6):387-97. doi: 10.1097/PAP.0b013e3182a92d0d. Adv Anat Pathol. 2013. PMID: 24113309 Free PMC article. Review.
-
Molecular biology of rhabdomyosarcoma.Clin Transl Oncol. 2007 Jul;9(7):415-9. doi: 10.1007/s12094-007-0079-3. Clin Transl Oncol. 2007. PMID: 17652054 Review.
Cited by
-
Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.Oncotarget. 2015 Apr 20;6(11):8722-35. doi: 10.18632/oncotarget.2726. Oncotarget. 2015. PMID: 25749378 Free PMC article.
-
Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands.Br J Cancer. 2017 Oct 24;117(9):1314-1325. doi: 10.1038/bjc.2017.305. Epub 2017 Sep 7. Br J Cancer. 2017. PMID: 28881358 Free PMC article.
-
Pediatric Rhabdomyosarcoma.Crit Rev Oncog. 2015;20(3-4):227-43. doi: 10.1615/critrevoncog.2015013800. Crit Rev Oncog. 2015. PMID: 26349418 Free PMC article. Review.
-
The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma.Virchows Arch. 2015 Aug;467(2):217-24. doi: 10.1007/s00428-015-1777-9. Epub 2015 Apr 26. Virchows Arch. 2015. PMID: 25912319
-
Current and Future Treatment Strategies for Rhabdomyosarcoma.Front Oncol. 2019 Dec 20;9:1458. doi: 10.3389/fonc.2019.01458. eCollection 2019. Front Oncol. 2019. PMID: 31921698 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous